May 5 Quick Takes: Argenx’s Vyvgart tops 1Q23 consensus sales

Argenx SE (Euronext:ARGX; NASDAQ:ARGX) continued its strong launch of FCRN inhibitor Vyvgart efgartigimod as the Dutch biotech announced $218 million in 1Q23 sales, above analyst consensus estimates. The figure was a 26% increase over 4Q22 sales and sets up the myasthenia gravis therapy to become a blockbuster, with a projected $1.3 billion in sales by year-end at its current 29% quarterly growth rate. Argenx also expects data in July from the Phase III ADHERE study of Vyvgart in chronic inflammatory demyelinating polyneuropathy, an indication that offers substantial opportunity to expand Vyvgart sales.

Chiesi Farmaceutici S.p.A. and Protalix Biotherapeutics Inc. (NYSE-M:PLX) said the European Commission approved pegunigalsidase alfa (PLX-102) to treat Fabry disease. The therapy is a plant cell-expressed recombinant form of human alpha galactosidase A. ...